VIDEO: Clinical Trial Results for Abaloparatide

Share this content:

Lorraine Fitzpatrick, MD, discusses with Rheumatology Advisor updated abaloparatide results from the ACTIVE phase 3 clinical trial (Study to Evaluate the Safety and Efficacy of BA058 for Prevention of Fracture in Postmenopausal Women, Identifier: NCT01343004).


Cosman F, Hattersley G, Miller P, Hu MY, Russo LAT, Riis B, Williams G, Fitzpatrick L. Abaloparatide-SC significantly reduces vertebral and nonvertebral fractures and increases bone mineral density (BMD) regardless of age, BMD T-Score, or prior fracture at baseline [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). Accessed November 23, 2016.

You must be a registered member of Endocrinology Advisor to post a comment.

Sign Up for Free e-Newsletters

CME Focus